AR107912A1 - Inhibidores de ret - Google Patents
Inhibidores de retInfo
- Publication number
- AR107912A1 AR107912A1 ARP170100670A ARP170100670A AR107912A1 AR 107912 A1 AR107912 A1 AR 107912A1 AR P170100670 A ARP170100670 A AR P170100670A AR P170100670 A ARP170100670 A AR P170100670A AR 107912 A1 AR107912 A1 AR 107912A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heteroalkyl
- considered independently
- cycloalkyl
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
En la presente memoria se describen compuestos que inhiben a RET de tipo silvestre y sus mutantes resistentes, composiciones farmacéuticas que incluyen a dichos compuestos, y métodos para utilizar dichos compuestos y composiciones. Reivindicación 1: Un compuesto que posee la fórmula estructural (1), o una sal del mismo apta para uso farmacéutico, donde: el anillo A es un anillo arilo o heteroarilo; cada uno de X¹ y X², considerado en forma independiente, se selecciona a partir de N y C(R⁶); cada R¹ y cada R⁷, considerado en forma independiente, se selecciona a partir de C₁₋₆ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, C₁₋₆ alcoxi, halo, C₁₋₆ heteroalquilo, cicloalquilo, arilo, heteroarilo, ariloxi, aralquilo, heterociclilo, heterociclilalquilo, nitro, ciano, -C(O)R, -OC(O)R, -C(O)OR, (C₁₋₆ alquilen)-C(O)R, -SR, -S(O)₂R, -S(O)₂-N(R)(R), (C₁₋₆ alquilen)-S(O)₂R, (C₁₋₆ alquilen)-S(O)₂-N(R)(R), -N(R)(R), -C(O)-N(R)(R), -N(R)-C(O)R, -N(R)-C(O)OR, -(C₁₋₆ alquilen)N(R)C(O)R, -N(R)S(O)₂R, y -P(O)(R)(R); donde cada uno de alquilo, alquenilo, alquinilo, alcoxi, heteroalquilo, cicloalquilo, arilo, heteroarilo, ariloxi, aralquilo, heterociclilo, y heterociclilalquilo, considerado en forma independiente, está sustituido con 0 - 5 casos de Rᵃ; o dos R¹ o dos R⁷ tomados en forma conjunta con los átomos de carbono a los que están unidos forman un anillo cicloalquilo o heterociclilo el cual, considerado en forma independiente, está sustituido con 0 - 5 casos de Rᵇ; cada uno de R², R³ᵃ, R³ᵇ, R⁴, R⁸ᵃ y R⁸ᵇ, considerado en forma independiente, se selecciona a partir de hidrógeno, C₁₋₆ alquilo, C₁₋₆ alcoxi, halo, hidroxilo, C₁₋₆ heteroalquilo, y -N(R)(R); donde cada alquilo, alcoxi, y heteroalquilo, considerado en forma independiente, opcionalmente está sustituido con 0 - 5 casos de Rᵃ; cada uno de R⁵ y R⁹, considerado en forma independiente, se selecciona a partir de hidrógeno, C₁₋₆ alquilo, y C₁₋₆ heteroalquilo; donde cada alquilo y heteroalquilo, considerado en forma independiente, opcionalmente está sustituido con 0 - 5 casos de Rᵃ; cada R⁶, considerado en forma independiente, se selecciona a partir de hidrógeno, C₁₋₆ alquilo, C₁₋₆ alcoxi, halo, C₁₋₆ heteroalquilo, y -N(R)(R); donde cada alquilo, alcoxi, y heteroalquilo, considerado en forma independiente, opcionalmente está sustituido con 0 - 5 casos de Rᵃ; cada R, considerado en forma independiente, se selecciona a partir de hidrógeno, hidroxilo, halo, tiol, C₁₋₆ alquilo, C₁₋₆ tioalquilo, C₁₋₆ alcoxi, C₁₋₆ heteroalquilo, cicloalquilo, cicloalquilalquilo, heteroarilalquilo, heterociclilo, y heterociclilalquilo, donde cada uno de alquilo, tioalquilo, alcoxi, heteroalquilo, cicloalquilo, cicloalquilalquilo, heteroarilalquilo, heterociclilo, y heterociclilalquilo, considerado en forma independiente, está sustituido con 0 - 5 casos de Rᵃ, o dos R tomados en forma conjunta con el o los átomos a los que están unidos forman un anillo cicloalquilo o heterociclilo el cual, considerado en forma independiente, está sustituido con 0 - 5 casos de Rᵇ; cada Rᵃ y cada Rᵇ, considerado en forma independiente, se selecciona a partir de C₁₋₆ alquilo, halo, hidroxilo, C₁₋₆ heteroalquilo, C₁₋₆ alcoxi, cicloalquilo, heterociclilo, o ciano, donde cada uno de alquilo, heteroalquilo, alcoxi, cicloalquilo y heterociclilo, considerado en forma independiente, está sustituido con 0 - 5 casos de R’; cada R’, considerado en forma independiente, se selecciona a partir de C₁₋₆ alquilo, C₁₋₆ heteroalquilo, halo, hidroxilo, cicloalquilo o ciano; o dos R’ tomados en forma conjunta con el o los átomos a los que están unidos forman un anillo cicloalquilo o heterociclilo; m es 0, 1, ó 2; y n es 0, 1, 2, ó 3.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662309748P | 2016-03-17 | 2016-03-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR107912A1 true AR107912A1 (es) | 2018-06-28 |
Family
ID=58428429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170100670A AR107912A1 (es) | 2016-03-17 | 2017-03-17 | Inhibidores de ret |
Country Status (5)
Country | Link |
---|---|
US (1) | US10183928B2 (es) |
AR (1) | AR107912A1 (es) |
TW (1) | TW201738228A (es) |
UY (1) | UY37155A (es) |
WO (1) | WO2017161269A1 (es) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20170098A (es) | 2010-05-20 | 2017-07-17 | Array Biopharma Inc | Compuestos macrociclicos como inhibidores de quinasa trk |
RS62233B1 (sr) | 2012-07-11 | 2021-09-30 | Blueprint Medicines Corp | Inhibitori receptora fibroblast faktora rasta |
US9499522B2 (en) | 2013-03-15 | 2016-11-22 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
RU2706235C2 (ru) | 2013-10-17 | 2019-11-15 | Блюпринт Медсинс Корпорейшн | Композиции, пригодные для лечения расстройств, связанных с kit |
EP3060560A1 (en) | 2013-10-25 | 2016-08-31 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
CA2992586A1 (en) | 2015-07-16 | 2017-01-19 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
CA2994819A1 (en) | 2015-07-24 | 2017-02-02 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to kit and pdgfr |
AU2016311426B2 (en) | 2015-08-26 | 2021-05-20 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to NTRK |
AU2016348402B2 (en) | 2015-11-02 | 2021-05-13 | Blueprint Medicines Corporation | Inhibitors of RET |
EP3377497A1 (en) | 2015-11-19 | 2018-09-26 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
US10183928B2 (en) | 2016-03-17 | 2019-01-22 | Blueprint Medicines Corporation | Inhibitors of RET |
DK3442977T3 (da) | 2016-04-15 | 2023-10-09 | Blueprint Medicines Corp | Inhibitorer af activinreceptorlignende kinase |
US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
US10035789B2 (en) | 2016-07-27 | 2018-07-31 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
CA3049136C (en) | 2017-01-18 | 2022-06-14 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
WO2018183712A1 (en) | 2017-03-31 | 2018-10-04 | Blueprint Medicines Corporation | Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr |
WO2018213329A1 (en) | 2017-05-15 | 2018-11-22 | Blueprint Medicines Corporation | Combinations of ret inhibitors and mtorc1 inhibitors and uses thereof for the treatment of cancer mediated by aberrant ret activity |
TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
TW202410896A (zh) | 2017-10-10 | 2024-03-16 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
WO2019079649A1 (en) | 2017-10-18 | 2019-04-25 | Blueprint Medicines Corporation | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-RELATED KINASE |
US11472802B2 (en) | 2018-01-18 | 2022-10-18 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors |
CN111971286B (zh) | 2018-01-18 | 2023-04-14 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物 |
CN110294745B (zh) * | 2018-03-22 | 2022-04-19 | 浙江海正药业股份有限公司 | 五元杂环类衍生物及其制备方法和其在医药上的用途 |
AU2019247766A1 (en) | 2018-04-03 | 2020-10-15 | Blueprint Medicines Corporation | RET inhibitor for use in treating cancer having a RET alteration |
CN112703014A (zh) | 2018-08-10 | 2021-04-23 | 缆图药品公司 | Egfr突变型癌症的治疗 |
WO2020035065A1 (zh) * | 2018-08-17 | 2020-02-20 | 南京明德新药研发有限公司 | 作为ret抑制剂的吡唑衍生物 |
JP2022500383A (ja) | 2018-09-10 | 2022-01-04 | アレイ バイオファーマ インコーポレイテッド | Retキナーゼ阻害剤としての縮合複素環式化合物 |
WO2020083332A1 (zh) * | 2018-10-24 | 2020-04-30 | 南京明德新药研发有限公司 | 作为ret抑制剂的嘧啶衍生物 |
WO2020083311A1 (zh) * | 2018-10-24 | 2020-04-30 | 南京明德新药研发有限公司 | 作为ret抑制剂的吡嗪衍生物 |
CN111285875B (zh) * | 2018-12-06 | 2023-02-03 | 苏州信诺维医药科技股份有限公司 | 一种杂环化合物、其应用及含其的药物组合物 |
CN111285882B (zh) * | 2018-12-07 | 2022-12-02 | 四川科伦博泰生物医药股份有限公司 | 稠环化合物、包含其的药物组合物及其制备方法和用途 |
CN111484479B (zh) * | 2019-01-25 | 2023-06-13 | 四川科伦博泰生物医药股份有限公司 | 氮杂环化合物、包含其的药物组合物及其制备方法和用途 |
CN111499613B (zh) * | 2019-01-31 | 2023-05-12 | 浙江海正药业股份有限公司 | N-甲酰胺衍生物、其制备方法及其在医药上的用途 |
EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
EP3950688A4 (en) * | 2019-04-03 | 2022-11-30 | Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory | SPIRO DERIVATIVE CONTAINING NITROGEN USED AS A RET INHIBITOR |
CN111808077B (zh) * | 2019-04-12 | 2023-05-02 | 浙江海正药业股份有限公司 | 哌嗪酰胺衍生物,其制备方法及其在医药上的用途 |
DK3856341T3 (da) | 2019-04-12 | 2023-12-04 | Blueprint Medicines Corp | Krystallinske former af (s)-1-(4-fluorphenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amin og fremgangsmåder til fremstilling deraf |
CN111961034A (zh) * | 2019-05-20 | 2020-11-20 | 浙江同源康医药股份有限公司 | 用作ret激酶抑制剂的化合物及其应用 |
EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
CN113135896A (zh) * | 2020-01-18 | 2021-07-20 | 正大天晴药业集团股份有限公司 | 作为ret抑制剂的甲基吡唑类衍生物 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
AR121914A1 (es) * | 2020-04-27 | 2022-07-20 | Lilly Co Eli | Compuestos útiles para inhibir la quinasa ret |
CA3197032A1 (en) | 2020-11-06 | 2022-05-12 | Eli Lilly And Company | Pyrazole derivatives as ret kinase inhibitors |
KR20240132251A (ko) | 2021-10-22 | 2024-09-03 | 유니버시티 오브 휴스턴 시스템 | 상피 조직의 만성 염증성 손상, 화생, 이형성증 및 암을 치료하기 위한 방법 및 조성물 |
CN117466901A (zh) * | 2022-07-23 | 2024-01-30 | 浙江海正药业股份有限公司 | 哌嗪酰胺衍生物的晶型及其制备方法和用途 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3704101A (en) | 2000-02-17 | 2001-08-27 | Amgen Inc | Kinase inhibitors |
CN1668306A (zh) | 2002-07-24 | 2005-09-14 | 辛辛那提大学 | 用于治疗与突变的 r e t激酶相关疾病的4-(4-甲基哌嗪-1-基甲基)-n-[4-甲基-3-((吡啶-3-基)嘧啶-2-基基氨)苯基]-苯甲酰胺 |
US20100047777A1 (en) | 2005-05-26 | 2010-02-25 | The Johns Hopkins University | Methods for identifying mutations in coding and non-coding dna |
WO2007023382A2 (en) | 2005-08-25 | 2007-03-01 | Pfizer Inc. | Pyrimidine amino pyrazole compounds, potent kinase inhibitors |
US20090012045A1 (en) | 2007-06-26 | 2009-01-08 | Rigel Pharmaceuticals, Inc. | Methods of Treating Cell Proliferative Disorders |
EP2074118A2 (en) | 2007-07-09 | 2009-07-01 | AstraZeneca AB | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
WO2009014537A1 (en) | 2007-07-25 | 2009-01-29 | Hewlett-Packard Company | Systems and methods for detecting ink mixing |
WO2009100536A1 (en) | 2008-02-15 | 2009-08-20 | Methylgene Inc. | Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures |
JP2013509444A (ja) | 2009-10-30 | 2013-03-14 | アリアド・ファーマシューティカルズ・インコーポレイテッド | がんの治療方法及び治療用組成物 |
CN102811619B (zh) | 2009-11-13 | 2015-04-22 | 金纳斯克公司 | 激酶抑制剂 |
CN103764676A (zh) | 2011-08-04 | 2014-04-30 | 日本国立癌症研究中心 | Kif5b基因和ret基因的融合基因、以及以该融合基因为目标的判断癌症治疗有效性的方法 |
AU2012298884B2 (en) | 2011-08-23 | 2017-11-16 | Foundation Medicine, Inc. | Novel KIF5B-RET fusion molecules and uses thereof |
US20130096136A1 (en) | 2011-09-30 | 2013-04-18 | Methylgene Inc. | Inhibitors of Protein Tyrosine Kinase Activity |
US10023855B2 (en) | 2011-10-31 | 2018-07-17 | Macrogen, Inc. | Fusion protein comprising C-terminal domain of RET protein and use thereof as a diagnosing marker |
WO2013071093A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
RS62233B1 (sr) | 2012-07-11 | 2021-09-30 | Blueprint Medicines Corp | Inhibitori receptora fibroblast faktora rasta |
US20150177246A1 (en) | 2012-07-26 | 2015-06-25 | Lsip, Llc | Fusion gene of cep55 gene and ret gene |
JP6513567B2 (ja) * | 2012-09-07 | 2019-05-15 | エクセリクシス, インク. | 肺腺癌の治療で使用するためのmet、vegfr、およびretの阻害剤 |
HUE040055T2 (hu) | 2012-09-25 | 2019-02-28 | Chugai Pharmaceutical Co Ltd | RET inhibitor |
CN104870446B (zh) | 2012-11-07 | 2019-08-13 | 内尔维阿诺医学科学有限公司 | 取代的嘧啶基和吡啶基吡咯并吡啶酮类、其制备方法及其作为激酶抑制剂的用途 |
TWI629266B (zh) | 2012-12-28 | 2018-07-11 | 藍印藥品公司 | 纖維母細胞生長因子受體之抑制劑 |
JP6186012B2 (ja) | 2013-02-25 | 2017-08-23 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C−3アルキルおよびアルケニル修飾ベツリン酸誘導体 |
US9499522B2 (en) | 2013-03-15 | 2016-11-22 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
UA115264C2 (uk) | 2013-03-15 | 2017-10-10 | Глаксосмітклайн Інтеллектьюел Проперті Девелопмент Лімітед | Піридинові похідні як інгібітори реаранжованої у процесі трансфекції (ret) кінази |
WO2015006875A1 (en) | 2013-07-18 | 2015-01-22 | Methylgene Inc. | Process for the preparation of substituted pyrimidines |
EP3037547A1 (en) | 2013-08-20 | 2016-06-29 | National Cancer Center | New fusion gene detected in lung cancer |
RU2706235C2 (ru) | 2013-10-17 | 2019-11-15 | Блюпринт Медсинс Корпорейшн | Композиции, пригодные для лечения расстройств, связанных с kit |
WO2015058129A1 (en) | 2013-10-17 | 2015-04-23 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
EP3060560A1 (en) | 2013-10-25 | 2016-08-31 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
GB201321146D0 (en) | 2013-11-29 | 2014-01-15 | Cancer Rec Tech Ltd | Quinazoline compounds |
JP6061341B2 (ja) | 2013-12-06 | 2017-01-18 | 朝日インテック株式会社 | ガイドワイヤ |
US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
US9688680B2 (en) | 2014-08-04 | 2017-06-27 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
JP6538153B2 (ja) | 2014-09-10 | 2019-07-03 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Rearranged during transfection(ret)阻害剤としての新規な化合物 |
EP3517526B1 (en) | 2014-09-10 | 2020-08-19 | GlaxoSmithKline Intellectual Property Development Limited | Pyridinones as rearranged during transfection (ret) inhibitors |
PL3218378T3 (pl) | 2014-11-14 | 2020-10-19 | Nerviano Medical Sciences S.R.L. | Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych |
WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
CA2992586A1 (en) | 2015-07-16 | 2017-01-19 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
CA2994819A1 (en) | 2015-07-24 | 2017-02-02 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to kit and pdgfr |
AU2016311426B2 (en) | 2015-08-26 | 2021-05-20 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to NTRK |
CN105255927B (zh) | 2015-09-30 | 2018-07-27 | 温州医科大学附属第一医院 | 一种kiaa1217-ret融合基因 |
AU2016348402B2 (en) | 2015-11-02 | 2021-05-13 | Blueprint Medicines Corporation | Inhibitors of RET |
EP3377497A1 (en) | 2015-11-19 | 2018-09-26 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
US10183928B2 (en) | 2016-03-17 | 2019-01-22 | Blueprint Medicines Corporation | Inhibitors of RET |
DK3442977T3 (da) | 2016-04-15 | 2023-10-09 | Blueprint Medicines Corp | Inhibitorer af activinreceptorlignende kinase |
US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
US10035789B2 (en) | 2016-07-27 | 2018-07-31 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
WO2018049233A1 (en) | 2016-09-08 | 2018-03-15 | Nicolas Stransky | Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors |
-
2017
- 2017-03-17 US US15/462,255 patent/US10183928B2/en active Active
- 2017-03-17 TW TW106108946A patent/TW201738228A/zh unknown
- 2017-03-17 UY UY0001037155A patent/UY37155A/es not_active Application Discontinuation
- 2017-03-17 WO PCT/US2017/022969 patent/WO2017161269A1/en active Application Filing
- 2017-03-17 AR ARP170100670A patent/AR107912A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW201738228A (zh) | 2017-11-01 |
UY37155A (es) | 2017-10-31 |
US20170267661A1 (en) | 2017-09-21 |
US10183928B2 (en) | 2019-01-22 |
WO2017161269A1 (en) | 2017-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR107912A1 (es) | Inhibidores de ret | |
AR105836A1 (es) | Compuestos y composiciones útiles para tratar trastornos relacionados con ntrk | |
AR129635A2 (es) | Moduladores de tetrahidropiridopirazina de gpr6 | |
CO6251243A2 (es) | Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c | |
AR100702A1 (es) | Compuestos inhibidores de quinasa de unión tank | |
AR094299A1 (es) | Derivados de ftalazin-1(2h)-ona sustituidos | |
AR104176A1 (es) | Inhibidores de ido (indolamina-2,3-dioxigenasa) | |
AR098666A1 (es) | Compuestos de biarilacetamida y sus métodos de uso | |
AR107973A1 (es) | 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonista de apj | |
AR105459A1 (es) | Derivados de pirrolo[2,1-f][1,2,4]triazina útiles para tratar trastornos relacionados con kit y pdfgr | |
AR100033A1 (es) | Compuestos y composiciones para inhibir la actividad de shp2 | |
AR094300A1 (es) | Derivados de quinolonas | |
AR094557A1 (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn | |
AR090993A1 (es) | Pirazol indanil carboxamidas | |
AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
AR105928A1 (es) | Compuesto para usar composiciones que cambian de color | |
AR090572A1 (es) | Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos | |
AR095351A1 (es) | Inhibidores de histona desacetilasa (hdac) | |
AR093758A1 (es) | Inhibidores de aril lactama quinasa | |
BR112017019439A2 (pt) | inibidores kv1.3 e sua aplicação médica | |
AR101255A1 (es) | Derivados de isoindolinona | |
ES2571529T3 (es) | Nuevos derivados de isoquinolina sustituida | |
AR103582A1 (es) | Ciclopropabenzofuranil-piridopirazindionas | |
AR109042A1 (es) | COMPUESTOS MODULARES DE RORg | |
AR106548A1 (es) | Inhibidores de ret |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |